Related references
Note: Only part of the references are listed.A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis
Jun Keng Khoo et al.
JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY (2020)
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial
Luca Richeldi et al.
LANCET RESPIRATORY MEDICINE (2020)
Airway epithelial specific deletion of Jun-N-terminal kinase 1 attenuates pulmonary fibrosis in two independent mouse models
Jos L. van der Velden et al.
PLOS ONE (2020)
A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor
Toby M. Maher et al.
RESPIRATORY RESEARCH (2020)
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study
Ganesh Raghu et al.
LANCET RESPIRATORY MEDICINE (2019)
Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis
Nasreen Khalil et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)
Toby M. Maher et al.
BMJ OPEN RESPIRATORY RESEARCH (2019)
Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey
Catharina C. Moor et al.
ERJ OPEN RESEARCH (2019)
A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors GPR40 and GPR84
Lyne Gagnon et al.
AMERICAN JOURNAL OF PATHOLOGY (2018)
Impact of Lung Function Decline on Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis (IPF)
M. Kreuter et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
The Rho Kinase Isoforms ROCK1 and ROCK2 Each Contribute to the Development of Experimental Pulmonary Fibrosis
Rachel S. Knipe et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2018)
OPTN/SRTR 2016 Annual Data Report: Lung
M. Valapour et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2018)
Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
Kevin R. Flaherty et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis A Randomized Clinical Trial
Ganesh Raghu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review
Alex Diamantopoulos et al.
PHARMACOECONOMICS (2018)
Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial
Toby M. Maher et al.
LANCET RESPIRATORY MEDICINE (2018)
Diagnosis of Idiopathic Pulmonary Fibrosis An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis Results of the INJOURNEY Trial
Carlo Vancheri et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Genetics of idiopathic pulmonary fibrosis: from mechanistic pathways to personalised medicine
Paolo Spagnolo et al.
JOURNAL OF MEDICAL GENETICS (2017)
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
Martin Kolb et al.
THORAX (2017)
Autoimmunity to Vimentin Is Associated with Outcomes of Patients with Idiopathic Pulmonary Fibrosis
Fu Jun Li et al.
JOURNAL OF IMMUNOLOGY (2017)
Effects of CTGF Blockade on Attenuation and Reversal of Radiation-Induced Pulmonary Fibrosis
Sebastian Bickelhaupt et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease
Ana L. Mora et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions
Jonathan A. Galli et al.
RESPIROLOGY (2017)
Effects of CTGF Blockade on Attenuation and Reversal of Radiation-Induced Pulmonary Fibrosis
Sebastian Bickelhaupt et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Epithelial cell senescence: an adaptive response to pre-carcinogenic stresses?
Corinne Abbadie et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2017)
Galectin-3 Is Associated with Restrictive Lung Disease and Interstitial Lung Abnormalities
Jennifer E. Ho et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
Type V Collagen in Health, Disease, and Fibrosis
Ki M. Mak et al.
ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY BIOLOGY (2016)
FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis
Ganesh Raghu et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy
Bernt van den Blink et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
Association Between Interstitial Lung Abnormalities and All-Cause Mortality
Rachel K. Putman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial
Juergen Behr et al.
LANCET RESPIRATORY MEDICINE (2016)
Idiopathic pulmonary fibrosis: An update
Paolo Spagnolo et al.
ANNALS OF MEDICINE (2015)
Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis
David S. Wilkes et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials
Harold R. Collard et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review
John Hutchinson et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review
Ganesh Raghu et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis
Antoine Francois et al.
JOURNAL OF AUTOIMMUNITY (2015)
An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode
Andrea Doni et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis
Takashi Ogura et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis
Daryle J. DePianto et al.
THORAX (2015)
The Rho Kinases: Critical Mediators of Multiple Profibrotic Processes and Rational Targets for New Therapies for Pulmonary Fibrosis
Rachel S. Knipe et al.
PHARMACOLOGICAL REVIEWS (2015)
Revealing the Pathogenic and Aging-related Mechanisms of the Enigmatic Idiopathic Pulmonary Fibrosis An Integral Model
Moises Selman et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Talmadge E. King et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Rituximab in severe, treatment-refractory interstitial lung disease
Gregory J. Keir et al.
RESPIROLOGY (2014)
Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11
Ganesh Raghu et al.
LANCET RESPIRATORY MEDICINE (2014)
Pathogenesis of Idiopathic Pulmonary Fibrosis
Paul J. Wolters et al.
Annual Review of Pathology-Mechanisms of Disease (2013)
Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis
Yong Zhou et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
MUC5B Promoter Polymorphism and Interstitial Lung Abnormalities
Gary M. Hunninghake et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Type V Collagen Induced Tolerance Suppresses Collagen Deposition, TGF-β and Associated Transcripts in Pulmonary Fibrosis
Ragini Vittal et al.
PLOS ONE (2013)
Interstitial Lung Abnormalities in a CT Lung Cancer Screening Population: Prevalence and Progression Rate
Gong Yong Jin et al.
RADIOLOGY (2013)
Regulation of Transforming Growth Factor-β1-driven Lung Fibrosis by Galectin-3
Alison C. MacKinnon et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)
Pulmonary Autotaxin Expression Contributes to the Pathogenesis of Pulmonary Fibrosis
Nikos Oikonomou et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2012)
The telomere syndromes
Mary Armanios et al.
NATURE REVIEWS GENETICS (2012)
CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis
Kenneth E. Lipson et al.
FIBROGENESIS & TISSUE REPAIR (2012)
Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis
Brett Ley et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF)
Masato Kono et al.
CLINICA CHIMICA ACTA (2011)
Lung Volumes and Emphysema in Smokers with Interstitial Lung Abnormalities
George R. Washko et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
LPA Receptors: Subtypes and Biological Actions
Ji Woong Choi et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2010)
Serum Amyloid P Therapeutically Attenuates Murine Bleomycin-Induced Pulmonary Fibrosis via Its Effects on Macrophages
Lynne A. Murray et al.
PLOS ONE (2010)
Lysophosphatidic Acid Induces alpha v beta 6 Integrin-Mediated TGF-beta Activation via the LPA2 Receptor and the Small G Protein G alpha(q)
Ming Yan Xu et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
c-Jun N-Terminal Kinase 1 Is Required for the Development of Pulmonary Fibrosis
John F. Alcorn et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2009)
The regulation of inflammation by galectin-3
Neil C. Henderson et al.
IMMUNOLOGICAL REVIEWS (2009)
Serum Amyloid P Inhibits Fibrosis Through FcγR-Dependent Monocyte-Macrophage Regulation in Vivo
Ana P. Castano et al.
SCIENCE TRANSLATIONAL MEDICINE (2009)
Inhibition of integrin alpha v beta 6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis
Khalid Puthawala et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Applications for ROCK kinase inhibiton
Michael F. Olson
CURRENT OPINION IN CELL BIOLOGY (2008)
Jun N-terminal kinase 1 regulates epithelial-to-mesenchymal transition induced by TGF-β1
John F. Alcorn et al.
JOURNAL OF CELL SCIENCE (2008)
JNK signaling in apoptosis
D. N. Dhanasekaran et al.
ONCOGENE (2008)
The lysophosphatidic acid receptor LPA(1) links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak
Andrew M. Tager et al.
NATURE MEDICINE (2008)
Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P
Darrell Pilling et al.
JOURNAL OF IMMUNOLOGY (2007)
Antisense oligonucleotide inhibition of Heat Shock Protein (HSP) 47 improves bleomycin-induced pulmonary fibrosis in rats
Satoshi Hagiwara et al.
RESPIRATORY RESEARCH (2007)
Interstitial and vascular type V collagen morphologic disorganization in usual interstitial pneumonia
Edwin Roger Parra et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2006)
The G-protein coupled receptor, GPR84 regulates IL-4 production by T lymphocytes in response to CD3 crosslinking
C Venkataraman et al.
IMMUNOLOGY LETTERS (2005)
Role of autoimmunity in organ allograft rejection: a focus on immunity to type V collagen in the pathogenesis of lung transplant rejection
TL Sumpter et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2004)
Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF
LH Pan et al.
EUROPEAN RESPIRATORY JOURNAL (2001)
Involvement of collagen-binding heat shock protein 47 and procollagen type I synthesis in idiopathic pulmonary fibrosis: Contribution of type II pneumocytes to fibrosis
T Iwashita et al.
HUMAN PATHOLOGY (2000)
Share Paper
